Sino Biological US, Inc. has announced the launch of ProPure, a groundbreaking line of ultra-pure, endotoxin-free recombinant proteins, produced at its Center for Bioprocessing (C4B) facility in Houston, Texas. This innovation is set to revolutionize immunology research, vaccine development, and therapeutic protein manufacturing by offering products with endotoxin levels below the limit of quantification (LOQ).

The ProPure product line is the result of advanced purification and production technologies, utilizing mammalian expression systems and proprietary purification protocols. These proteins are designed for sensitive applications where even minimal endotoxin contamination could jeopardize research outcomes or patient safety. Dr. Rob Burgess, Chief Business Officer at Sino Biological US, emphasized the company’s dedication to scientific excellence and product safety, highlighting how ProPure supports the highest standards of quality and consistency in both basic and translational science.

This launch reflects Sino Biological’s commitment to bioprocessing innovation and its support for the global life sciences community. Beyond standard offerings, the C4B facility also provides customized protein development services to meet specific research and production needs, further demonstrating the company’s flexibility and customer-focused approach.

The introduction of ProPure endotoxin-free proteins by Sino Biological represents a significant advancement in the field of life sciences, offering researchers and biomanufacturers a reliable resource for high-quality reagents. This development not only enhances the potential for breakthroughs in science and medicine but also sets a new benchmark for purity and safety in protein production.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Sino Biological Introduces ProPure Endotoxin-Free Proteins, Setting New Industry Standards.